Neumora Therapeutics (NMRA) Common Equity (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Common Equity of $70.7 million for Q1 2026, down 69.05% year-over-year from $228.4 million in Q1 2025, and down 31.95% quarter-over-quarter from $103.9 million in Q4 2025.
Neumora Therapeutics (NMRA) Common Equity (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $70.7 million for Q1 2026.
- In Q1 2026, Common Equity fell 69.05% year-over-year to $70.7 million; the TTM figure through Mar 2026 stood at $70.7 million (down 69.05% YoY), while the FY2025 annual figure was $103.9 million, down 63.82% from the prior year.
- Common Equity for Q1 2026 stood at $70.7 million, down from $103.9 million in the prior quarter.
- The five-year high for Common Equity was $512.7 million in Q3 2023, with the low at -$513.5 million in Q2 2023.
- The 5-year median for Common Equity is $182.9 million (2025), against an average of $83.5 million.
- The sharpest annual moves came in 2023 and 2026: Common Equity jumped 221.49% in 2023, then plunged 69.05% in 2026.
- Neumora Therapeutics' Common Equity stood at -$446.8 million in 2022, then jumped by 204.97% to $469.1 million in 2023, then slumped by 38.8% to $287.1 million in 2024, then sank by 63.82% to $103.9 million in 2025, then slumped by 31.95% to $70.7 million in 2026.
- Business Quant data shows NMRA's Common Equity at $70.7 million in Q1 2026, $103.9 million in Q4 2025, and $132.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 70.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.68 Mn |
| Dec 31, 2025 | 103.87 Mn |
| Sep 30, 2025 | 132.16 Mn |
| Jun 30, 2025 | 182.88 Mn |
| Mar 31, 2025 | 228.36 Mn |
| Dec 31, 2024 | 287.06 Mn |
| Sep 30, 2024 | 320.74 Mn |
| Jun 30, 2024 | 381.26 Mn |
| Mar 31, 2024 | 424.54 Mn |
| Dec 31, 2023 | 469.08 Mn |
| Sep 30, 2023 | 512.69 Mn |
| Jun 30, 2023 | -513.54 Mn |
| Mar 31, 2023 | -477.92 Mn |
| Dec 31, 2022 | -446.85 Mn |
| Sep 30, 2022 | -422.00 Mn |